Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:alsoKnownAs |
gptkb:gefitinib
|
| gptkbp:approvalYear |
2003
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XE02
|
| gptkbp:brand |
gptkb:Iressa
|
| gptkbp:CASNumber |
184475-35-2
|
| gptkbp:chemicalFormula |
C22H24ClFN4O3
|
| gptkbp:contraindication |
hypersensitivity to gefitinib
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:eliminatedIn |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
ZD1839
|
| gptkbp:mechanismOfAction |
gptkb:EGFR_tyrosine_kinase_inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea skin rash |
| gptkbp:target |
gptkb:epidermal_growth_factor_receptor
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:gefitinib
|
| gptkbp:bfsLayer |
7
|